News | January 13, 2022
Normalised quarter with impending margin pressure: ICICI Direct
ICICI Direct gives a preview on the earnings narrative for Q3FY22
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Key takeaways of recent quarter & conference call highlights
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Aurobindo has one of the most enduring generics ecosystems among peers
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
India sales grew 23.5% YoY with consolidation of Wockhardt products
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
Subscribe To Our Newsletter & Stay Updated
